Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortés(Villa Maria Hospital), Mary Ann Allison(Cornell University), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Dale E. Shuster(Daiichi Sankyo (United States)), Thomas Bachelot(Centre Léon Bérard), Joanne L. Blum(Texas Oncology), Henri Roché(Inserm), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Robert Paridaens(Cornell University), Mario Campone(Institut de Cancérologie de l'Ouest), Chris Twelves(University of Leeds), Renuka Gurnani(Cornell University), Fang Fang(Jinshan Hospital of Fudan University), Simon Ashworth(SUNY Upstate Medical University), Patricia E. Cole(Takeda (United States)), J. Wanders(Eisai (United Kingdom)), Elaine Richmond(Cornell University), Anthony Gonçalvès(Centre National de la Recherche Scientifique)
Cited by 217
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k